nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolvaptan—ABCB1—Dactinomycin—muscle cancer	0.211	0.258	CbGbCtD
Tolvaptan—ABCB1—Vincristine—muscle cancer	0.13	0.159	CbGbCtD
Tolvaptan—ABCB1—Etoposide—muscle cancer	0.119	0.146	CbGbCtD
Tolvaptan—ABCB1—Doxorubicin—muscle cancer	0.081	0.0993	CbGbCtD
Tolvaptan—ABCB1—Methotrexate—muscle cancer	0.0785	0.0962	CbGbCtD
Tolvaptan—CYP3A4—Vincristine—muscle cancer	0.0777	0.0952	CbGbCtD
Tolvaptan—CYP3A4—Etoposide—muscle cancer	0.0712	0.0872	CbGbCtD
Tolvaptan—CYP3A4—Doxorubicin—muscle cancer	0.0486	0.0595	CbGbCtD
Tolvaptan—Hyperuricaemia—Vincristine—muscle cancer	0.00384	0.0209	CcSEcCtD
Tolvaptan—Prothrombin level increased—Doxorubicin—muscle cancer	0.00364	0.0198	CcSEcCtD
Tolvaptan—Blood uric acid increased—Vincristine—muscle cancer	0.00362	0.0197	CcSEcCtD
Tolvaptan—Respiratory failure—Vincristine—muscle cancer	0.00362	0.0197	CcSEcCtD
Tolvaptan—Urine output increased—Vincristine—muscle cancer	0.00322	0.0175	CcSEcCtD
Tolvaptan—Hyperuricaemia—Etoposide—muscle cancer	0.00311	0.0169	CcSEcCtD
Tolvaptan—Polyuria—Vincristine—muscle cancer	0.00294	0.016	CcSEcCtD
Tolvaptan—Blood uric acid increased—Etoposide—muscle cancer	0.00294	0.016	CcSEcCtD
Tolvaptan—Hypernatraemia—Doxorubicin—muscle cancer	0.00284	0.0155	CcSEcCtD
Tolvaptan—Deep vein thrombosis—Methotrexate—muscle cancer	0.00284	0.0154	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Dactinomycin—muscle cancer	0.0026	0.0142	CcSEcCtD
Tolvaptan—Hyponatraemia—Vincristine—muscle cancer	0.00259	0.0141	CcSEcCtD
Tolvaptan—Dehydration—Vincristine—muscle cancer	0.0024	0.0131	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Vincristine—muscle cancer	0.00233	0.0127	CcSEcCtD
Tolvaptan—Vaginal haemorrhage—Doxorubicin—muscle cancer	0.00202	0.011	CcSEcCtD
Tolvaptan—Hyperuricaemia—Methotrexate—muscle cancer	0.00186	0.0101	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Etoposide—muscle cancer	0.00185	0.01	CcSEcCtD
Tolvaptan—Urinary tract disorder—Vincristine—muscle cancer	0.00176	0.0096	CcSEcCtD
Tolvaptan—Respiratory failure—Methotrexate—muscle cancer	0.00176	0.00956	CcSEcCtD
Tolvaptan—Blood uric acid increased—Methotrexate—muscle cancer	0.00176	0.00956	CcSEcCtD
Tolvaptan—Connective tissue disorder—Vincristine—muscle cancer	0.00176	0.00955	CcSEcCtD
Tolvaptan—Urethral disorder—Vincristine—muscle cancer	0.00175	0.00953	CcSEcCtD
Tolvaptan—Pulmonary embolism—Methotrexate—muscle cancer	0.00173	0.00939	CcSEcCtD
Tolvaptan—Cardiac disorder—Vincristine—muscle cancer	0.00166	0.00902	CcSEcCtD
Tolvaptan—Angiopathy—Vincristine—muscle cancer	0.00162	0.00882	CcSEcCtD
Tolvaptan—Ill-defined disorder—Dactinomycin—muscle cancer	0.00162	0.00879	CcSEcCtD
Tolvaptan—Hyperuricaemia—Doxorubicin—muscle cancer	0.00161	0.00877	CcSEcCtD
Tolvaptan—Mediastinal disorder—Vincristine—muscle cancer	0.00161	0.00876	CcSEcCtD
Tolvaptan—Renal failure—Etoposide—muscle cancer	0.00159	0.00862	CcSEcCtD
Tolvaptan—Blood bilirubin increased—Doxorubicin—muscle cancer	0.00158	0.0086	CcSEcCtD
Tolvaptan—Malaise—Dactinomycin—muscle cancer	0.00157	0.00854	CcSEcCtD
Tolvaptan—Urine output increased—Methotrexate—muscle cancer	0.00156	0.00849	CcSEcCtD
Tolvaptan—Ecchymosis—Methotrexate—muscle cancer	0.00156	0.00849	CcSEcCtD
Tolvaptan—Blood uric acid increased—Doxorubicin—muscle cancer	0.00152	0.00828	CcSEcCtD
Tolvaptan—Pulmonary embolism—Doxorubicin—muscle cancer	0.0015	0.00813	CcSEcCtD
Tolvaptan—Hyperkalaemia—Doxorubicin—muscle cancer	0.00147	0.00799	CcSEcCtD
Tolvaptan—Discomfort—Dactinomycin—muscle cancer	0.00146	0.00797	CcSEcCtD
Tolvaptan—Urinary tract disorder—Etoposide—muscle cancer	0.00143	0.00778	CcSEcCtD
Tolvaptan—Polyuria—Methotrexate—muscle cancer	0.00143	0.00776	CcSEcCtD
Tolvaptan—Urethral disorder—Etoposide—muscle cancer	0.00142	0.00772	CcSEcCtD
Tolvaptan—Anorexia—Dactinomycin—muscle cancer	0.00135	0.00737	CcSEcCtD
Tolvaptan—Ecchymosis—Doxorubicin—muscle cancer	0.00135	0.00735	CcSEcCtD
Tolvaptan—Cardiac disorder—Etoposide—muscle cancer	0.00134	0.00731	CcSEcCtD
Tolvaptan—Angiopathy—Etoposide—muscle cancer	0.00131	0.00714	CcSEcCtD
Tolvaptan—Immune system disorder—Etoposide—muscle cancer	0.00131	0.00711	CcSEcCtD
Tolvaptan—Mediastinal disorder—Etoposide—muscle cancer	0.0013	0.0071	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Methotrexate—muscle cancer	0.00128	0.00696	CcSEcCtD
Tolvaptan—Anaphylactic shock—Vincristine—muscle cancer	0.00127	0.00691	CcSEcCtD
Tolvaptan—Nervous system disorder—Vincristine—muscle cancer	0.00125	0.00677	CcSEcCtD
Tolvaptan—Decreased appetite—Dactinomycin—muscle cancer	0.00124	0.00672	CcSEcCtD
Tolvaptan—Dysgeusia—Etoposide—muscle cancer	0.00123	0.00671	CcSEcCtD
Tolvaptan—Anorexia—Vincristine—muscle cancer	0.00121	0.00658	CcSEcCtD
Tolvaptan—Feeling abnormal—Dactinomycin—muscle cancer	0.00117	0.00637	CcSEcCtD
Tolvaptan—Ill-defined disorder—Etoposide—muscle cancer	0.00117	0.00636	CcSEcCtD
Tolvaptan—Renal impairment—Doxorubicin—muscle cancer	0.00114	0.0062	CcSEcCtD
Tolvaptan—Malaise—Etoposide—muscle cancer	0.00114	0.00618	CcSEcCtD
Tolvaptan—Breast disorder—Methotrexate—muscle cancer	0.00113	0.00616	CcSEcCtD
Tolvaptan—Body temperature increased—Dactinomycin—muscle cancer	0.00112	0.00611	CcSEcCtD
Tolvaptan—Hypoglycaemia—Doxorubicin—muscle cancer	0.00111	0.00605	CcSEcCtD
Tolvaptan—Loss of consciousness—Etoposide—muscle cancer	0.00111	0.00602	CcSEcCtD
Tolvaptan—Cerebrovascular accident—Doxorubicin—muscle cancer	0.00111	0.00602	CcSEcCtD
Tolvaptan—Decreased appetite—Vincristine—muscle cancer	0.0011	0.006	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Vincristine—muscle cancer	0.0011	0.00596	CcSEcCtD
Tolvaptan—Hyponatraemia—Doxorubicin—muscle cancer	0.00109	0.00593	CcSEcCtD
Tolvaptan—Constipation—Vincristine—muscle cancer	0.00109	0.00591	CcSEcCtD
Tolvaptan—Gastrointestinal haemorrhage—Doxorubicin—muscle cancer	0.00109	0.0059	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.00107	0.0058	CcSEcCtD
Tolvaptan—Discomfort—Etoposide—muscle cancer	0.00106	0.00577	CcSEcCtD
Tolvaptan—Hypersensitivity—Dactinomycin—muscle cancer	0.00105	0.0057	CcSEcCtD
Tolvaptan—Anaphylactic shock—Etoposide—muscle cancer	0.00103	0.00559	CcSEcCtD
Tolvaptan—Asthenia—Dactinomycin—muscle cancer	0.00102	0.00555	CcSEcCtD
Tolvaptan—Blood creatinine increased—Doxorubicin—muscle cancer	0.00102	0.00553	CcSEcCtD
Tolvaptan—Dehydration—Doxorubicin—muscle cancer	0.00101	0.00549	CcSEcCtD
Tolvaptan—Body temperature increased—Vincristine—muscle cancer	0.001	0.00546	CcSEcCtD
Tolvaptan—Skin disorder—Etoposide—muscle cancer	0.000999	0.00543	CcSEcCtD
Tolvaptan—Orthostatic hypotension—Doxorubicin—muscle cancer	0.000991	0.00539	CcSEcCtD
Tolvaptan—Breast disorder—Doxorubicin—muscle cancer	0.000981	0.00534	CcSEcCtD
Tolvaptan—Anorexia—Etoposide—muscle cancer	0.00098	0.00533	CcSEcCtD
Tolvaptan—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000977	0.00532	CcSEcCtD
Tolvaptan—Diarrhoea—Dactinomycin—muscle cancer	0.000972	0.00529	CcSEcCtD
Tolvaptan—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000957	0.00521	CcSEcCtD
Tolvaptan—Renal failure—Methotrexate—muscle cancer	0.00095	0.00516	CcSEcCtD
Tolvaptan—Hypersensitivity—Vincristine—muscle cancer	0.000935	0.00509	CcSEcCtD
Tolvaptan—Asthenia—Vincristine—muscle cancer	0.000911	0.00496	CcSEcCtD
Tolvaptan—Decreased appetite—Etoposide—muscle cancer	0.000894	0.00486	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Etoposide—muscle cancer	0.000888	0.00483	CcSEcCtD
Tolvaptan—Constipation—Etoposide—muscle cancer	0.00088	0.00478	CcSEcCtD
Tolvaptan—Diarrhoea—Vincristine—muscle cancer	0.000869	0.00473	CcSEcCtD
Tolvaptan—Pollakiuria—Doxorubicin—muscle cancer	0.000867	0.00471	CcSEcCtD
Tolvaptan—Urinary tract disorder—Methotrexate—muscle cancer	0.000856	0.00466	CcSEcCtD
Tolvaptan—Urethral disorder—Methotrexate—muscle cancer	0.00085	0.00462	CcSEcCtD
Tolvaptan—Feeling abnormal—Etoposide—muscle cancer	0.000848	0.00461	CcSEcCtD
Tolvaptan—Hyperglycaemia—Doxorubicin—muscle cancer	0.000846	0.0046	CcSEcCtD
Tolvaptan—Nausea—Dactinomycin—muscle cancer	0.000844	0.00459	CcSEcCtD
Tolvaptan—Dizziness—Vincristine—muscle cancer	0.00084	0.00457	CcSEcCtD
Tolvaptan—Renal failure—Doxorubicin—muscle cancer	0.000822	0.00447	CcSEcCtD
Tolvaptan—Body temperature increased—Etoposide—muscle cancer	0.000813	0.00442	CcSEcCtD
Tolvaptan—Cardiac disorder—Methotrexate—muscle cancer	0.000805	0.00438	CcSEcCtD
Tolvaptan—Headache—Vincristine—muscle cancer	0.000795	0.00433	CcSEcCtD
Tolvaptan—Angiopathy—Methotrexate—muscle cancer	0.000787	0.00428	CcSEcCtD
Tolvaptan—Immune system disorder—Methotrexate—muscle cancer	0.000783	0.00426	CcSEcCtD
Tolvaptan—Mediastinal disorder—Methotrexate—muscle cancer	0.000782	0.00425	CcSEcCtD
Tolvaptan—Hypersensitivity—Etoposide—muscle cancer	0.000758	0.00412	CcSEcCtD
Tolvaptan—Malnutrition—Methotrexate—muscle cancer	0.000755	0.00411	CcSEcCtD
Tolvaptan—Nausea—Vincristine—muscle cancer	0.000754	0.0041	CcSEcCtD
Tolvaptan—Urinary tract disorder—Doxorubicin—muscle cancer	0.000742	0.00403	CcSEcCtD
Tolvaptan—Dysgeusia—Methotrexate—muscle cancer	0.000739	0.00402	CcSEcCtD
Tolvaptan—Asthenia—Etoposide—muscle cancer	0.000738	0.00401	CcSEcCtD
Tolvaptan—Connective tissue disorder—Doxorubicin—muscle cancer	0.000738	0.00401	CcSEcCtD
Tolvaptan—Urethral disorder—Doxorubicin—muscle cancer	0.000736	0.004	CcSEcCtD
Tolvaptan—Pruritus—Etoposide—muscle cancer	0.000728	0.00396	CcSEcCtD
Tolvaptan—Diarrhoea—Etoposide—muscle cancer	0.000704	0.00383	CcSEcCtD
Tolvaptan—Ill-defined disorder—Methotrexate—muscle cancer	0.0007	0.00381	CcSEcCtD
Tolvaptan—Cardiac disorder—Doxorubicin—muscle cancer	0.000697	0.00379	CcSEcCtD
Tolvaptan—Angiopathy—Doxorubicin—muscle cancer	0.000681	0.00371	CcSEcCtD
Tolvaptan—Malaise—Methotrexate—muscle cancer	0.000681	0.0037	CcSEcCtD
Tolvaptan—Dizziness—Etoposide—muscle cancer	0.00068	0.0037	CcSEcCtD
Tolvaptan—Immune system disorder—Doxorubicin—muscle cancer	0.000678	0.00369	CcSEcCtD
Tolvaptan—Mediastinal disorder—Doxorubicin—muscle cancer	0.000677	0.00368	CcSEcCtD
Tolvaptan—Malnutrition—Doxorubicin—muscle cancer	0.000654	0.00356	CcSEcCtD
Tolvaptan—Headache—Etoposide—muscle cancer	0.000644	0.0035	CcSEcCtD
Tolvaptan—Dysgeusia—Doxorubicin—muscle cancer	0.00064	0.00348	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	0.000638	0.00347	CcSEcCtD
Tolvaptan—Discomfort—Methotrexate—muscle cancer	0.000635	0.00345	CcSEcCtD
Tolvaptan—Anaphylactic shock—Methotrexate—muscle cancer	0.000616	0.00335	CcSEcCtD
Tolvaptan—Nausea—Etoposide—muscle cancer	0.000611	0.00332	CcSEcCtD
Tolvaptan—Ill-defined disorder—Doxorubicin—muscle cancer	0.000607	0.0033	CcSEcCtD
Tolvaptan—Nervous system disorder—Methotrexate—muscle cancer	0.000604	0.00329	CcSEcCtD
Tolvaptan—Skin disorder—Methotrexate—muscle cancer	0.000598	0.00325	CcSEcCtD
Tolvaptan—Malaise—Doxorubicin—muscle cancer	0.000589	0.00321	CcSEcCtD
Tolvaptan—Anorexia—Methotrexate—muscle cancer	0.000587	0.00319	CcSEcCtD
Tolvaptan—Syncope—Doxorubicin—muscle cancer	0.000586	0.00319	CcSEcCtD
Tolvaptan—Loss of consciousness—Doxorubicin—muscle cancer	0.000575	0.00312	CcSEcCtD
Tolvaptan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	0.000553	0.00301	CcSEcCtD
Tolvaptan—Discomfort—Doxorubicin—muscle cancer	0.00055	0.00299	CcSEcCtD
Tolvaptan—Dry mouth—Doxorubicin—muscle cancer	0.000544	0.00296	CcSEcCtD
Tolvaptan—Decreased appetite—Methotrexate—muscle cancer	0.000536	0.00291	CcSEcCtD
Tolvaptan—Anaphylactic shock—Doxorubicin—muscle cancer	0.000533	0.0029	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Methotrexate—muscle cancer	0.000532	0.00289	CcSEcCtD
Tolvaptan—Shock—Doxorubicin—muscle cancer	0.000525	0.00285	CcSEcCtD
Tolvaptan—Nervous system disorder—Doxorubicin—muscle cancer	0.000523	0.00285	CcSEcCtD
Tolvaptan—Skin disorder—Doxorubicin—muscle cancer	0.000518	0.00282	CcSEcCtD
Tolvaptan—Anorexia—Doxorubicin—muscle cancer	0.000509	0.00277	CcSEcCtD
Tolvaptan—Feeling abnormal—Methotrexate—muscle cancer	0.000508	0.00276	CcSEcCtD
Tolvaptan—Body temperature increased—Methotrexate—muscle cancer	0.000487	0.00265	CcSEcCtD
Tolvaptan—Decreased appetite—Doxorubicin—muscle cancer	0.000464	0.00252	CcSEcCtD
Tolvaptan—Gastrointestinal disorder—Doxorubicin—muscle cancer	0.000461	0.00251	CcSEcCtD
Tolvaptan—Constipation—Doxorubicin—muscle cancer	0.000456	0.00248	CcSEcCtD
Tolvaptan—Hypersensitivity—Methotrexate—muscle cancer	0.000454	0.00247	CcSEcCtD
Tolvaptan—Asthenia—Methotrexate—muscle cancer	0.000442	0.0024	CcSEcCtD
Tolvaptan—Feeling abnormal—Doxorubicin—muscle cancer	0.00044	0.00239	CcSEcCtD
Tolvaptan—Pruritus—Methotrexate—muscle cancer	0.000436	0.00237	CcSEcCtD
Tolvaptan—Body temperature increased—Doxorubicin—muscle cancer	0.000422	0.00229	CcSEcCtD
Tolvaptan—Diarrhoea—Methotrexate—muscle cancer	0.000422	0.00229	CcSEcCtD
Tolvaptan—Dizziness—Methotrexate—muscle cancer	0.000407	0.00222	CcSEcCtD
Tolvaptan—Hypersensitivity—Doxorubicin—muscle cancer	0.000393	0.00214	CcSEcCtD
Tolvaptan—Headache—Methotrexate—muscle cancer	0.000386	0.0021	CcSEcCtD
Tolvaptan—Asthenia—Doxorubicin—muscle cancer	0.000383	0.00208	CcSEcCtD
Tolvaptan—Pruritus—Doxorubicin—muscle cancer	0.000377	0.00205	CcSEcCtD
Tolvaptan—Nausea—Methotrexate—muscle cancer	0.000366	0.00199	CcSEcCtD
Tolvaptan—Diarrhoea—Doxorubicin—muscle cancer	0.000365	0.00199	CcSEcCtD
Tolvaptan—Dizziness—Doxorubicin—muscle cancer	0.000353	0.00192	CcSEcCtD
Tolvaptan—Headache—Doxorubicin—muscle cancer	0.000334	0.00182	CcSEcCtD
Tolvaptan—Nausea—Doxorubicin—muscle cancer	0.000317	0.00172	CcSEcCtD
